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ABSTRACT
Bone mineral density (BMD) is an important factor linked to bone health. Little is known of the prevalence of low BMD and its associated
risk factors in an urban underserved population. Between 2001 and 2004, we recruited 338 subjects who completed drug use and
medical history questionnaires, underwent hormonal measurements, and underwent whole-body dual-energy X-ray absorptiometry
(DXA) for evaluation of BMD and body composition. Of these, 132 subjects had site-specific DXA (lumbar spine and hip) performed.
OsteoporosiswasdefinedasaT-scoreof–2.5orlessformen50years ofageandolderandpostmenopausalwomenandaZ-scoreof–2.0
or less in men younger than 50 years of age and premenopausal women at either the lumbar spine, total hip, or femoral neck, according
to National Osteoporosis Foundation (NOF) guidelines. The cohort consisted of mostly African-American, middle-aged people with a
high prevalence of illicit drug use, 50% HIV
þ, and 39% hepatitis C
þ. Osteoporosis was identified in 22% of subjects (24 men, 5 women),
with the majority of cases (90%) attributable to osteoporosis at the lumbar spine. Osteoporosis was more common in men than in
women. Lower whole-body BMD among women was associated with multiple risk factors, but only with lower lean mass among men.
Osteoporosiswashighlyprevalentinmen,mainlyatthespine.Theriskfactorsforbonelossinthispopulationneedtobefurtherclarified.
Screening men for osteoporosis starting at age 50 might be warranted in this population given the multiple risk factors and the
unexpectedly high prevalence of low BMD.  2011 American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is a disease of the bone characterized by
decreased bone mineral density (BMD) and bone quality
with a resulting increased risk in skeletal fragility and fracture.
(1)
Fractures related to osteoporosis represent a large burden for
society and high health care costs for prolonged hospitalization
and complications of increased morbidity and mortality, as well
as indirect costs of declining functioning, nursing home
placement,andreduced qualityoflife.
(2) Publichealthawareness
of osteoporosis has lead to increased interest in identifying the
fracture risk factors because fractures are preventable by
screening appropriate populations and initiating effective
therapy. Most of the data regarding osteoporosis has been
derived from postmenopausal female white populations. Only
recently is osteoporosis in men gaining attention
(3,4) and, to a
lesser extent, osteoporosis in African Americans.
Men and women living in the inner city have multiple risk
factors for osteoporosis, but the prevalence of low BMD is not
well defined in this population. Human immunodeficiency virus
(HIV) infection, hepatitis C infection, alcohol abuse, smoking,
illicit drug use, hypogonadism, homelessness, and poor
nutritional status are common in inner-city populations
(5–9)
and have been associated with increased risk of osteoporosis
and fractures.
(10–13)
In this study, we aimed to determine the prevalence of
osteoporosis and reduced BMD in a cohort of inner-city
Baltimore’s population and investigate the risk factors associated
with BMD.
Subjects and Methods
Study population
The Study of HIV, Injection Drug Use, Nutrition and Endocrinol-
ogy (SHINE) is a cross-sectional study of volunteers in Baltimore
designed to evaluate the effects of HIV infection and drug use on
multiple endocrine and metabolic parameters. Between 2001
and 2004, subjects were recruited from local medical and HIV
clinics, community methadone maintenance programs, an
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388existing cohort of injection drug users, homeless shelters, and by
word of mouth. Subjects between 18 and 65 years of age were
eligible for recruitment, which was stratified by gender and HIV
status. Individuals with any of the following characteristics were
excluded: (1) known gonadal dysfunction by medical history,
(2) other significant medical problems resulting in a serum
creatinine concentration more than three times the upper limit
of normal (ULN), transaminases more than three times ULN, or
hematocritlessthan 25%,and(3)untreatedendocrineproblems,
such as hypothyroidism, as indicated by medical history. All
volunteers had provided written informed consent before
participation. The study was approved by the Johns Hopkins
University Institutional Review Board.
Drug and alcohol use classification
Drug-use status was divided into three groups of (1) no use, (2)
occasional (<3 times/week), and (3) heavy drug users ( 3 times/
week) over the past 6 months. Drug use included heroin
(injection, snorting, or smoking), cocaine (snorting or injection),
speedball (injection), crack/freebase, marijuana, and street
methadone.Thosewho wereenrolled inamethadonetreatment
program for at least 3 months were grouped separately. Subjects
also were stratified by alcohol use into three groups of (1)no use,
(2) moderate (<3 drinks/day), and (3) heavy use ( 3 drinks/day)
during the past 6 months. Drinking equivalents for one drink
included8fluidouncesofbeerorwine,4fluidouncesofliquoror
malt, or 1 fluid ounce of vodka. Subjects who reported smoking
in the past 6 months were considered smokers.
HIV and hepatitis C infection
HIV status was determined by (1) self-reported serostatus, (2)
self-report of antiretroviral therapy, or (3) ELISA testing followed
by Western blot confirmation for subjects without documenta-
tion of HIV status. Hepatitis C status was self-reported.
Biochemical measurements
Hormonal measurements included free testosterone (fT), follicle-
stimulating hormone (FSH), luteinizing hormone (LH), dehydroe-
piandrosterone (DHEA), and estradiol from morning serum
samples collected between 8:00 and 10:00 a.m. in the Clinical
Trials Unit at the Johns Hopkins University School of Medicine.
Free testosterone was measured by equilibrium dialysis (Esoterix,
Inc., Austin, TX, USA) with a normal range of 52 to 280ng/dL for
men. Intraassay coefficients of variation (CV) ranged from 6.6% to
9.4%, and interassay CV ranged from 9.1% to 11.9%. Males were
considered hypogonadal if they had an fT level of less than
52ng/dL or were on testosterone-replacement therapy. Estradiol
wasmeasuredbyradioimmunoassay(Esoterix,Inc.)inwhichintra-
and interassay CVs were 5.2% and 8.0%, respectively. This variable
was divided into tertiles from lowest (1) to highest (3) when
evaluating its relation to BMD. LH and FSH were measured by
immunochemiluminometric assay (ICMA), forwhich theintra- and
interassay CVs were 3.4% and 3.8%, respectively, for LH, and 3.2%
and 6.7%, respectively, for FSH. Females were considered
postmenopausal if they had a FSH concentration of less than
50 mIU/mL, age of 51 years of greater, or they self-reported when
the FSH level was greater than 30 and 50 mIU/mL or less.
Using frozen serum samples, parathyroid hormone (PTH) and
vitamin D levels were obtained later on 126 subjects of the
subset with site-specific dual-energy X-ray absorptiometry (DXA)
scans. Intact PTH (iPTH) was measured by two-site ELISA (Alpco
Diagnostics, Salem, NH, USA) with intraassay CVs of 2.8% to 3.0%
and interassay CVs of 5.1% to 5.5%. Reading the assay at 450nm,
iPTH concentrations were valid up to about 200pg/mL as the
upper limit. Secondary hyperparathyroidism was defined as iPTH
greaterthan 65pg/mL.25-Hydroxyvitamin D[25(OH)D]level was
measured by radioimmunoassay (DiaSorin, Stillwater, MN, USA)
with an intraassay CV of 8.6% to 11.7% and interassay CV of 8.2%
to 11.0%. The lower limit was measured at 1.5ng/mL or less.
Vitamin D deficiency was defined as 25(OH)D concentration of
15ng/mL or less.
Measurement of serum inflammatory markers, including
tumor necrosis factor a (TNF-a), high-sensitivity interleukin-6
(hs-IL6), and high-sensitivity C-reactive protein (hs-CRP), were
completed at the Advanced Chemistry Laboratory at the Johns
Hopkins University using an ALPO assay (Windham, NH, USA).
TNF-a was measured by ELISA, where intra- and interassay CVs
were 8.2% and 6.1%, respectively. hs-IL6 was measured by ELISA
with intra- and interassay CVs of 5.1% and 5.0%, respectively.
hs-CRP was measured by ELISA with intra- and interassay CVs of
6.3% and 2.2%, respectively. These markers were divided into
tertiles from lowest (1) to the highest (3) level to evaluate the
relation between BMD and inflammatory markers.
Body composition and BMD measurements
Body massindex[BMI¼weight (kg)/height
2(m
2)] wascalculated
for all subjects
Whole-body DXA scans were performed on a Hologic 4500A
machine with QDA4500A software Version 9.03 (Hologic Inc,
Bedford, MA, USA) to obtain measures of total lean body mass
(LBM, kg), fat body mass (kg), as well as whole-body BMD
(WBMD, g/cm
2). A subset of the participants had BMD assessed
regionally at the lumbar spine and hip (total and femoral neck).
For this subset of patients, T-scores and Z-scores were calculated
from the site-specific BMD measures using normative data from
the manufacturer matched for gender and race.
(14,15) Subjects
who specified race other than African American, white, or
Hispanic (n¼5) were considered white for consistency of
definition (non-African American) because data are available
only for whites, African Americans, and Hispanics. Osteoporosis
was defined as a T-score of –2.5 or less for men 50 years of age or
older and postmenopausal women and a Z-score of –2.0 or less
in men younger than 50 years of age and premenopausal
women at either the lumbar spine, total hip, or femoral neck,
according to National Osteoporosis Foundation (NOF) guide-
lines.
(16) Reduced BMD was defined as a T-score of less than –1.0.
Osteopenia was defined as –2.5<T-score<–1.
Statistical analysis
Data were stratified by gender, and the demographic character-
istics and BMD measures of the study participants were
described. Normality of the distributions for each variable was
checked by plotting histograms. The first part of the analysis
included the larger cohort (total study population) with WBMD
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obtain more power and perform correlative analysis stratified by
gender. WBMD closely reflects assessment by site-specific
measures and has an excellent correlation with spine BMD in
predicting osteoporosis.
(17) The analysis examined the relation-
ship between WBMD and various independent variables (risk
factors) and was stratified by gender. One-way ANOVA was used
to determine the association between WBMD and categorical
independentvariables,andlinearregressionanalysiswasusedto
assess the relationbetween WBMDandcontinuous independent
variables. The association between WBMDand multiple variables
was done by stepwise backward regression analysis using a p
value of .25 to enter and .1 to remain in the model. Variables
tested included age, gender, race (African American or other),
smoking status (yes/no), alcohol/drug use (none, moderate, or
heavy), methadone program (yes/no), hypogonadal/menopau-
sal, hepatitis C status, HIV status, BMI or LBMþfat mass, and lab
parameters (ie, DHEA, estradiol, TNF-a, IL6, and CRP) in tertiles.
The final model locked in age and race and was stratified by
gender because these variables are known risk factors for low
BMD.
The second part of the analysis investigated the subset of
participants with site-specific DXA, where osteoporosis (as
defined earlier) was considered the dependent variable
(dichotomous). A chi-square test was used to determine the
group differences of osteoporosis among categorical indepen-
dent variables. Regression analysis was used to determine the
relation between osteoporosis and continuous independent
variables. Multivariate backward stepwise regression was
performed similar to the WBMD model described earlier. Smaller
sample size limited stratification by gender, but the final model
locked in gender, along with age and race. Risk factors tested
were the same as used for WBMD analysis. In addition, we
evaluated the relationship between osteoporosis and vitamin D
deficiency status [25(OH)D 15ng/mL) and the presence of
secondary hyperparathyroidism (iPTH>65pg/mL).
p Values less than .05 were considered significant. Statistical
analysis was performed on JMP Statistical Software 7.0.2 (2007,
SAS Institute, Inc., Cary, NC, USA).
Results
Demographic characteristics of study participants
Thecohortconsistedofatotalof338subjectswhohadmeasures
of WBMD, including 187 males and 151 females. Demographic
characteristics stratified by gender are presented in Table 1, with
similar distributions among women and men. The population
consisted of a relatively young group (mean age 42.8 years) of
mostly African-American (93.8%) inner-city men and women of
low socioeconomic status (SES); 27% of the population was
homelessintheprioryear,15%wereemployedatthetimeofthe
study, 51% reported income of $10,000 or less in the prior year,
and 28% reported no legal income. Seventy percent reported
moderateorheavydruguse,and11%reportedtheconsumption
of three or more alcohol drinks per day. Most were smokers
(84%). Ninety-nine subjects (30%) were enrolled in a methadone
program, of which 66 also were active drug users. Half (50%) the
population was HIV
þ, and 38.7% were hepatitis C
þ. The
prevalence of hypogonadism was 25% in men and 21% in
women (postmenopausal). One subject was on testosterone-
replacement therapy (fT¼2.2ng/dL, therefore hypogonadal by
biochemical definition), one subject reported corticosteroid use;
and three subjects were taking anticonvulsant medications. Men
had a statistically significant lower BMI than women (24.8 and
27.4kg/m
2, respectively, p<.05) as well as lower fat mass but
higher LBM and WBMD (Table 1).
Factors associated with WBMD
When stratified by gender, the relation of WBMD to various
independent risk factors showed major differences among men
and women (Table 2). Whereas only LBM was positively related
with BMD in men, multiple risk factors showed significant
associations in women. In females, older age, non-African
American race, postmenopausal status, lower LBM, and
methadone use showed significant association with lower
BMD in univariate analysis. Similar results were obtained when
BMI replaced fat mass and LBM, with BMI as a significant
determinant. Methadone use was an independent determinant
of WBMD in women, where the association was not affected by
simultaneous adjustment for other factors. Moderate (<3 drinks/
day) consumption of alcohol was significantly associated with
higher BMD in women. Women having the highest levels of
DHEA and estradiol had significantly higher BMD measures,
consistent with the known benefits of estrogen on bone.
Independent determinants of lower BMD in women included
increasing age, non-African-American race, methadone, and
lower LBM (Table 3). There was a trend toward lower BMD by HIV
status in women (p¼.11). Among HIV-infected women (n¼65),
we explored whether the self-report of antiretroviral therapy was
associated with WBMD. After adjustment for age, non-African-
American race, methadone use, and LBM, HIV therapy was not
associated with lower WBMD (–0.002, p¼.89).
Demographic and BMD characteristics of the
subpopulation with site-specific DXA
Ofthe338subjects, 132subjects receivedsite-specific DXAscans
of the spine and hip. Demographic characteristics of this group
were similar to those of the larger cohort (Table 1), with similar
distribution among men and women (not shown). Men had
lower BMI values than women (24.4 versus 26.2kg/m
2,
respectively), lower fat mass, but higher LBM (59.3 versus
46kg, respectively) as well as higher WMBD (1.26 versus 1.20g/
cm
2, respectively), all with statistically significant differences
betweenmenandwomen(p<.05).Regressionanalysisrevealed
strong correlation between WMBD and spine BMD (r¼0.57,
p<.0001), between WMBD and total-hip BMD (r¼0.53,
p<.0001), and between WBMD and hip femoral neck BMD
(r¼0.46, p<.0001). Reduced BMD was present in 69% of the
population, with twice as many men having osteoporosis of the
hip region (total or femoral neck) compared with women.
Osteoporosis, as defined by the NOF, was identified in 22%
of subjects (24 men and 5 women), with the majority of cases
(90%) attributable to osteoporosis of the lumbar spine (Table 3,
Fig. 1A, B).
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The relation between osteoporosis and different independent
variables is shown in Table 4. Men were nearly four times more
likely to have osteoporosis than women [odds ratio (OR)¼3.6,
95%confidenceinterval(CI)1.3–10].IncreasingLBMwastheonly
other variable associated with lower risk of osteoporosis
(OR¼0.84, 95% CI 0.76–0.94) in univariable analysis (Table 4).
Similar results were obtained when BMI replaced lean and fat
mass.
Of the 126 subjects with site-specific DXA and biochemical
measurements of 25(OH)D and iPTH, 124 (98%) had 25(OH)D
Table 1. Population Demographics and Biochemical Measures
Variable
WBMD cohort (n¼338)
Site-specific DXA cohort
M (187) F (151) (n¼132)
Age (mean, SD) 43.3 (7.2) 42.1 (7.6) 42.5 (8)
Male — — 83 (63%)
African American 175 (94%) 141 (93%) 124 (94%)
Homeless (in the past year) 48 (26%) 41 (28%) 35 (27%)
Employed (at time of study) 32 (17%) 19 (13%) 12 (9%)
High school or GED completion 114 (62%) 77 (51%) 72 (55%)
Smoking
a 145 (82%) 128 (87%) 102 (80%)
Alcohol
b
No use 74 (41%) 73 (50%) 55 (43%)
<3 drinks/day 85 (48%) 58 (39%) 57 (45%)
 3 drinks/day 20 (11%) 16 (11%) 16 (13%)
Methadone
c 43 (24%) 56 (37%) 33 (25%)
Drug use
d
No use 49 (28%) 47 (33%) 23 (18%)
<3 times/week 74 (42%) 44 (31%) 47 (37%)
 3 times/week 54 (30%) 53 (37%) 58 (45%)
Hepatitis C
e 71 (39%) 58 (40%) 49 (38%)
HIV
f 103 (56%) 65 (43%) 67 (51%)
Hypogonadal
g/menopausal
h 44 (25%) 32 (21%) 36 (28%)
BMI (kg/m2) (mean, SD) 24.8 (4.4) 27.4 (6.6) 25.1 (5)
Lean body mass (kg) (mean, SD) 59.3 (7.9) 47.2 (8.1) 54.4 (9.8)
Fat body mass (kg) (mean, SD) 13.4 (7.4) 22.3 (11) 15.8 (8.9)
25 (OH) D (ng/ml) (mean, SD) — — 16.1 (0.65)
25 (OH)D< 15 — — 61 (48%)
iPTH (pg/ml) (mean, SD) — — 51.3 (2.2)
iPTH> 65 — — 28 (22%)
TNF-a (pg/ml) (mean, SE) N¼243 2.9 (0.26) 2.6 (0.3) 2.8 (0.3)
hsCRP (ng/ml) (mean, SE) N¼243 3.9 (0.6) 5.1 (0.9) 6.3 (1.1)
hsIL-6 (pg/ml) (mean, SE) N¼ 238 3.3 (0.23) 3.8 (0.3) 3 (0.2)
MF
Free T (ng/dL) (mean, SE) N¼318 89.1 (4.9) 5.5 (1.4) 83.4 (6.8) 2.6 (0.3)
Estradiol (pg/ml) (mean, SE) N¼327 32.7 (1.5) 52.5 (4.5) 37.1 (2.2) 52.4 (6.4)
LH (mIU/ml) (mean, SE) N¼328 5.6 (0.26) 12 (1.2) 5.7 (0.4) 12.9 (2.4)
FSH (mIU/ml) (mean, SE) N¼328 5.8 (0.5) 15.9 (1.7) 5.9 (0.8) 19.3 (3.5)
DHEA (ng/dL) (mean, SE) N¼328 161 (8.5) 107 (7.8) 178 (15) 119 (15)
Note: Items in boldface denote statistically significant difference (p<.05) between males and females.
aDetermined by answering yes to having smoked cigarettes in the past 6 months (irrespective of quantity).
bEquivalent of 1 drink is 8 fluid ounces of beer or wine, 4 fluid ounces of liquor or malt, and 1 fluid ounce of vodka.
cIncludes subjects who are enrolled in a methadone treatment program for at least 3 months.
dIncludes marijuana, crack/freebase, cocaine (snorting, injection), speedball (injection), heroin (smoking, snorting, injection), and street methadone in
the past 6 months.
eSelf-report.
fSelf-report, HIV-positive by testing, or history of past or present use of antiretroviral therapy.
gDefined as having a free testosterone level<52pg/mL or currently on testosterone-replacement therapy.
hDefined as having FSH level>50 mIU/mL, age 51 years, or FSH level>30 mIU/mL and  50 mIU/mL and answered yes to having gone through
menopause.
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Variable
Male Female
Univariate
b estimate
Multivariate
a
b estimate
Univariate
b estimate
Multivariate
b
b estimate
Lean body mass (kg) 0.005
    0.006
    0.007
    0.006
   
Age (per increase of 5 years) 0.003 0.002  0.03
    0.02
   
Race (non-African American/African American)  0.04 0.04  0.18
     0.14
   
Methadone  0.03 NS  0.05
   0.05
   
HIV
c 0.02 NS  0.04  0.03
Smoking
d 0.02 NS  0.04 NS
Alcohol
e NS NS
0 (no use) Ref Ref
1( <3 drinks/day) 0.03 0.05
 
2(  3 drinks/day)  0.007 0.01
Drug use
f NS NS
0 (no use) Ref Ref
1( <3 times/week) 0.005 0.01
2(  3 times/week)  0.02 0.05
Hypogonadal
g/menopausal
h  0.01 NS  0.1
    NS
Hepatitis C
i 0.005 NS  0.02 NS
Fat body mass (kg) <0.01 NS <0.01
  NS
BMI (kg/m
2) 0.007
   NS 0.005
   (Not included)
DHEA (tertiles)
j NS NS
1 Ref Ref
2  0.04 0.05
3 0.0004 0.07
  
Estradiol (tertiles)
j NS NS
1 Ref Ref
2  0.003 0.04
3 0.02 0.08
  
IL-6 (tertiles)
j NS NS
1 Ref Ref
2  0.006  0.01
3  0.004  0.02
CRP (tertiles)
j NS NS
1 Ref Ref
2  0.03 0.03
3  0.007 0.03
TNF-a (tertiles)
j NS NS
1 Ref Ref
2  0.03  0.03
3 0.006  0.03
NS¼nonsignificant.
Note: Items in boldface denote significant p values:
 p<.05.
  p<.01.
   p<.0001.
aFinal model R
2 value¼0.12, R
2 adjusted¼0.1, p<.0001, n¼186.
bFinal model R
2 value¼0.38, R
2 adjusted¼0.36, p<.0001, n¼150.
cSelf-report, HIV
þ by testing, or history of past or present use of antiretroviral therapy.
dDetermined by answering yes to having smoked cigarettes in the past 6 months (irrespective of quantity).
eEquivalent of 1 drink is 8 fluid ounces of beer or wine, 4 fluid ounces of liquor or malt, and 1 fluid ounce of vodka.
fIncludesmarijuana,crack/freebase,cocaine(snorting,injection),speedball(injection),heroin(smoking,snorting,injection),andstreetmethadoneinthe
past 6 months.
gDefined as having free testosterone level<52pg/mL or currently on testosterone-replacement therapy.
hDefined as having an FSH level>50 mIU/mL, age 51 years, or an FSH level >30 and  50 mIU/mL and answered yes to having gone through
menopause.
iSelf-report.
jObtained by plotting continuous lab values, 0 representing the lowest tertile, 1 the middle tertile, and 2 the highest tertile.
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had 25(OH)D level   15ng/mL. Secondary hyperparathyroidism
(iPTH>65pg/mL) was present in 22% of subjects. 25(OH)D was
inversely related to iPTH (r¼0.08, p¼.001). However, the
prevalence of secondary hyperparathyroidism was similar in
those with and without vitamin D deficiency (28% versus 17%,
p¼.14). Osteoporosis was not associated with vitamin D
deficiency or secondary hyperparathyroidism (Table 4). Site-
specific Z-scores were similar regardless of the presence of
vitamin D deficiency and/or secondary hyperparathyroidism
(Table 5).
Discussion
In this predominately middle-aged, low-income, African-Amer-
ican, inner-city population in Baltimore, MD, we found a very
high prevalence of osteoporosis, particularly at the lumbar spine.
BMD in the osteoporotic range was more common in men than
in women. Among men, only lower LBM was a significant
positive determinant of lower WBMD, whereas in women,
multiple factors were associated with lower WBMD, including
age, white race, methadone use, and lower LBM.
The prevalence of osteoporosis was higher than expected in
this population, which was 94% African American. Race plays an
important role in BMD, where African Americans attain higher
peak mass than whites, Hispanics, and Asians during pub-
erty.
(18,19) In population-based studies, African Americans have
13% to 18% higher hip BMD measures
(20–24) and 2% to 12%
higher spine BMD measures
(20–25) than whites. The National
Health and Nutrition Examination Survey III (NHANES III) data,
Table 3. Bone Mineral Density Measures
Site Measure Male Female Total
Whole-body data (n¼338) (n¼187) (n¼151)
Total BMD mean (g/cm
2) (SD) 1.27 (0.13) 1.19 (0.13) 1.23 (0.14)
Site-specific data (n¼132) (n¼83) (n¼49)
Total hip
BMD mean (g/cm
2) (SD) 1.02 (0.15) 0.98 (0.15) 1 (0.15)
Proportion with reduced BMD
a 42 (50.6%) 12 (24.5%) 54 (41%)
Proportion with osteopenia
b 40 (48.2%) 11 (22.4%) 51 (38.6%)
Proportion with osteoporosis
c 2 (2.4%) 1 (2%) 3 (2.3%)
Hip-femoral neck
BMD mean (g/cm
2) (SD) 0.94 (0.15) 0.90 (0.15) 0.93 (0.15)
Proportion with reduced BMD
a 39 (46.9%) 12 (24.5%) 51 (38.6%)
Proportion with osteopenia
b 37 (44.6%) 11 (22.4%) 48 (36.4%)
Proportion with osteoporosis
c 2 (2.4%) 1 (2%) 3 (2.3%)
Lumbar spine
BMD mean (g/cm
2) (SD) 1.04 (0.15) 1.04 (0.15) 1.04 (0.15)
Proportion with reduced BMD
a 54 (65%) 25 (51%) 79 (60%)
Proportion with osteopenia
b 39 (47%) 21 (42.9%) 60 (45.5%)
Proportion with osteoporosis
c 23 (27.7%) 5 (10.2%) 28 (21.2%)
Reduced BMD any site
d 63 (75.9%) 28 (57%) 91 (68.9%)
Osteopenia any site
d 46 (55.4%) 23 (46.9%) 69 (52.3%)
Osteoporosis any site
d 24 (28.9%) 5 (10.2%) 29 (22%)
Note: Items in boldface denote statistically significant difference (p<.05) between males and females.
aReduced BMD defined as having a T-score<–1.
bOsteopenia defined as having –2.5<T-score<–1.
cOsteoporosis defined as having a Z-score –2 for pre-menopausal women and men<50 years of age and T-score –2.5 for postmenopausal women
and men 50 years of age.
dTotal hip, hip femoral neck, or lumbar spine.
Fig. 1. (A) Male BMD measures. (B) Female BMD measures
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femoral neck BMD measures in African-American compared with
white men.
(26,27) Compared with African Americans in a random
samplefrom Boston(meanage48years),wherethemajorityhad
good health, our African-American men had similar WBMD and
femoral neck BMD measures, but our men had 6.4% lower total-
hip and 6.3% lower spine BMD measures.
(20) Other populations
of African Americans also have shown high rates of osteoporosis.
In a population of African-American male veterans (mean age 64
years, BMI 29kg/m
2), the prevalence of osteopenia (39%) and
osteoporosis (7%) was unexpectedly high in a relatively low-risk
population.
(28) The contributing factors associated with low BMD
in this cohort were not described. Together with our findings,
these observations suggest that clinicians should be aware that
African-American race is not necessarily a protective factor for
low BMD. While we cannot conclude that African-American race
is associated with lower BMD because our cohort was
overwhelmingly African American and no similar cohort of
white subjects is available for comparison, our data suggest that
more aggressive bone density screening may be appropriate in
some African-American populations.
Another major finding in our study was the higher prevalence
of osteoporosis in men than in women. Rates of BMD lower in
men than in women have been described among groups with
depression
(29) and in subjects on methadone maintenance,
where in one study the prevalence of osteoporosis was higher in
men than in women (61% versus 20%).
(9) Plausible explanations
for such high rates among men included secondary causes of
osteoporosis such as reduced physical activity and diet. In our
study, we investigated some secondary causes such as
hypogonadism, vitamin D deficiency, and alcohol and tobacco
abuse; however, none was significantly related to lower BMD.
The prevalence of vitamin D deficiency was high in our DXA
subpopulation [48% with 25(OH)D<15ng/mL], a finding that is
common among African Americans.
(30–32) However, neither
vitamin D deficiency nor secondary hyperparathyroidism could
account for the high prevalence of osteoporosis in our
population. It has been suggested that the adverse effects of
vitamin D deficiency on bone in African Americans are less
Table 4. Potential Determinants of BMD by Site-Specific DEXA:
Odds Ratio (95% CI) for having Osteoporosis
a
Variable
Univariate
analysis
Multivariate
b
analysis
Gender (male/female) 3.58 (1.27–10.12)
  22.9 (5.01–105.5)
   
Lean body mass
c (kg) 0.97 (0.93–1.01) 0.88 (0.825–0.945)
  
Age (per increase of
5 years)
0.84 (0.65–1.08) 0.86 (0.64 1.14)
Race (non-African
American/African
American)
3.96 (0.93–16.94) 3.32 (0.71 15.4)
Smoking
d 0.7 (0.26–1.89) NS
Alcohol
e NS
0 (no use) Ref
1( <3 drinks/day) 1.07 (0.43–2.67)
2(   3 drinks/day) 1.82 (0.52–6.32)
Drug use
f NS
0 (no use) Ref
1( <3 times/week) 0.74 (0.21–2.58)
2( >3 times/week) 1.26 (0.4–3.97)
Hypogonadal
g/
menopausal
h
1.01 (0.4–2.53) NS
Hepatitis C
i 1.22 (0.53–2.84) NS
HIV
j 1.77 (0.76–4.12) NS
Fat body mass (kg) 0.99 (0.99–0.99) NS
BMI (kg/m
2) 0.84 (0.76–0.94)
   NS
Methadone 1.52 (0.61–3.8) NS
DHEA (tertiles)
k NS
1 Ref
2 2.43 (0.85–6.95)
3 1.15 (0.39–3.42)
Estradiol (tertiles)
k NS
1 Ref
2 1.35 (0.47–3.82)
3 0.55 (0.17–1.77)
IL-6 (tertiles)
k NS
1 Ref
2 0.77 (0.25–2.35)
3 0.78 (0.23–2.63)
CRP (tertiles)
k NS
1 Ref
2 0.49 (0.15–1.56)
3 0.32 (0.1–1.06)
TNF-a (tertiles)
k NS
1 Ref
2 1.08 (0.35–3.27)
3 0.46 (0.13–1.6)
Vitamin D deficient
l NS
0 Ref
1 0.69 (0.29–1.59)
Secondary
hyperparathyroidism
m
NS
0 Ref
1 1.15 (0.41–2.97)
NS¼nonsignificant.
Note: Items in boldface denote significant p values
 p<.05.
  p<.01.
   p<.0001.
aOsteoporosis defined as having a T-score –2.5 for postmenopausal
women and men aged 50 years of age or a Z-score –2 for preme-
nopausal women and men<50 years of age. T-score/Z-score measured
at the lumbar spine, total hip, or hip femoral neck (lowest value taken).
bFinal model, R
2¼0.193; max-rescaled R
2¼0.297, p¼.0001, n¼132.
cIn kilograms, measured by whole-body DXA scan.
dDetermined by answering yes to having smoked cigarettes in the past
6 months (without account to quantity).
eEquivalent of 1 drink is 8 fluid ounces of beer or wine, 4 fluid ounces of
liquor or malt, and 1 fluid ounce of vodka.
fIncludes marijuana, crack/freebase, cocaine (snorting, injection),
speedball (injection), heroin (smoking, snorting, injection), and street
methadone in the past 6 months.
gDefined as having a free testosterone level<52pg/mL or currently on
testosterone-replacement therapy
hDefinedashavinganFSHlevel>50mIU/mL,age 51years,orhaving
FSH>30 or 50 mIU/mL and answered yes to having gone through
menopause.
iSelf-report.
jSelf-report, HIV
þ by testing, or history of past or present use of
antiretroviral therapy.
kObtained by plotting continuous lab values: 0¼the lowest tertile,
1¼the middle tertile, and 2¼the highest tertile.
lDeficiency defined as having 25(OH)D level 15ng/mL.
mDefined as having an iPTH level>65pg/mL.
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resistance.
(33) This hypothesis requires further investigation
because it has clear implications for the definition of vitamin
D deficiency in African-American populations.
Most of the osteoporosis in our cohort (>90%) was found in
the spine. The spine consists mainly of trabecular bone, which is
highly metabolically active and is characterized by increased
bone remodeling. In young men, loss of trabecular bone has
been related to low physical activity.
(34) Lower-spine BMD can
have important clinical consequences. In the Osteoporotic
Fractures in Men (MrOS) study, a prospective community study
of 5995 men aged 65 years and older, a significant association
was observed between lumbar spine BMD and vertebral
fractures and a weaker but significant association between
lumbar spine BMD and risk of hip fracture.
(35,36) In contrast to the
population of MrOs, which was predominantly white (90%), our
population was 94% African American. It is unknown whether
the low spine BMD observed in our cohort is predictive of higher
rates of clinical vertebral and nonvertebral fracture because
historical data regarding incidence fractures after DXA assess-
ment were not captured.
The risk factors for lower BMD in our cohort differed between
men and women. In both men and women, LBM was an
important correlate of BMD. However, among women, other
factors were associated with lower BMD, including age, non-
African-American race, methadone use, and HIV status. Other
studies have shown differences in risk factors among women
and men. The Framingham Osteoporosis Study, which examined
risk factors for longitudinal bone loss, found only weight to be
related to lower BMD in men, whereas weight, alcohol intake,
and estrogen therapy constituted risk factors in women.
(37)
Consistent risk factors for low BMD in a systematic review of
healthy men aged 50 years or older included advanced age,
smoking, and low weight.
(38) Since our population was enriched
by injection drug users having multiple risk factors that are
different from the populations studied in the literature, other risk
factors might be present that merit further investigation as low
BMD determinants among men in this population.
Consistent with the literature, BMI was a significant determi-
nant of BMD in both men and women.
(39,40) When evaluating the
components of BMI that contribute to the relation with BMD, our
analysis showed that LBM rather than fat mass predicted BMD in
both women and men compared with some studies that found
LBM in men but fat mass in women to be BMI mediators.
(41–43)
Despite the high prevalence of many osteoporosis risk factors,
surprisingly, we found no association between heavy alcohol,
drug, and tobacco use; hepatitis C infection; hypogonadism; and
inflammatory markers and lower BMD.
Implications and Conclusion
Osteoporosis of the spine was strikingly high in this cohort of
inner-city, high-risk African-American males. Although the
causes of this finding in our population are unclear, the high
prevalence of osteoporosis in this young population could
indicate even higher rates in similar older subjects. There is
evidence of suboptimal recognition and diagnosis of osteo-
porosis among African Americans and in men,
(44–46) and such
disparities in detection can be more pronounced in underserved
populations such as ours. Current osteoporosis guidelines
suggest DXA screening in postmenopausal women and men
aged 50 to 70 years based on clinical risk factors. Given the
high burden of osteoporosis in this population, screening for
osteoporosis could be warranted in this high-risk subpopulation
at a younger age (50 years). It is uncertain that such high rates of
osteoporosis could translate to increased fracture rate in the
future, but further studies are needed to better understand and
assess the implications.
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